Tetraxim – Sanofi
Indication and Usage –
TETRAXIM vaccine is indicated in the joint prevention of diphtheria, tetanus, pertussis and poliomyelitis:
- for primary vaccination in infants from the age of 2 months,
- for booster vaccination, one year after primary vaccination during the second year of life.
- for booster vaccination between 5 and 13 years of age, according to official recommendations.
Dosage and Administration –
- Administer via the intramuscular route.
- Administration should preferably be performed in the antero-lateral side of the thigh (middle third) in infants and in the deltoid area in children.
- Primary vaccination: 3 injections given at an interval of one month, i.e. according to the official schedule, at the age of 2, 3, 4 months.
- Booster vaccination: 1 injection one year after primary vaccination, i.e. usually, between 16 and 18 months.
- Booster vaccination between 5 and 13 years of age: 1 injection.
Contraindications –
- Hypersensitivity to any of the active substances of TETRAXIM, any of the excipients listed, glutaraldehyde, neomycin, streptomycin, or polymyxin B (used during the manufacturing process and which may be present as traces) and to a pertussis vaccine (acellular or whole cell).
- Life-threatening reaction after previous administration of the same vaccine or a vaccine containing the same substances.
- Vaccination must be postponed in case of febrile or acute disease.
- Evolving encephalopathy.
- Encephalopathy within 7 days of administration of a previous dose of any vaccine containing pertussis antigens (whole cell or acellular pertussis vaccines).
Adverse reactions –
- Very common adverse reactions include: Loss of appetite; Nervousness, irritability. Abnormal crying. Somnolence. Headache. Vomiting. Myalgia. Injection-site erythema, Injection-site pain, Injection-site oedema, Fever ≥38°C, Malaise.
- Common adverse reactions include: Insomnia, sleep disturbances, Diarrhoea, Injection-site induration.
- Uncommon adverse reactions include: Prolonged Inconsolable crying, Injection-site redness and oedema ≥5 cm, Fever ≥39°C.
- Rare adverse reactions include: Fever >40°C.
Drug interactions and other interactions –
- It can be administered simultaneously with the MMR VAXPRO vaccine or with the HB VAXPRO vaccine, but in two separate sites.
- TETRAXIM vaccine can be associated or combined with the Haemophilus influenzae type b conjugate vaccine (Act-HIB).
